Journal Home
Search for

Volume 4, Issue 2, Pages 171-175 (June 2010)


View previous. 9 of 21 View next.

Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis — A prospective study

Alan C. MossCorresponding Author Informationemail address, Nabeel Chaudhary, Melissa Tukey, Jahvari Junior, Didia Cury, Kenneth R. Falchuk, Adam S. Cheifetz

Received 29 September 2009; received in revised form 7 October 2009; accepted 8 October 2009. published online 18 November 2009.

Abstract 

Background

Patient adherence to medications, particularly mesalamine, is reported to be low in patients with ulcerative colitis. We sought to determine whether a nurse-delivered patient-support program could improve medication adherence in these patients.

Methods

Patients prescribed mesalamine for ulcerative colitis prospectively received either a 23week, nurse-delivered, patient support program (PSP) by phone, or standard care (SC). Medication adherence and quality of life were measured before and at 3 and 6months after the program started.

Results

Eighty-one patients completed the study; 60 who received standard care, and 21 who received the PSP. Patients were in remission (mean SCAI score 3) at enrollment. Mean % of prescribed mesalamine refilled was 71% and 74% in the SC and PSP groups at 3months (p=0.7), and 73% and 84% at 6months (p=0.4). The proportion of adherent patients at 3months (39% vs 44%, p=0.7) and 6months (50% vs 67%, p=0.3) were similar between the SC and PSP groups. There was no association between use of the PSP and adherence at 3 (OR 1.2, 95% CI 0.4 to 3.8) or 6months (OR 2, 95% CI 0.6 to 7). The change from baseline in SIBDQ scores were similar between SC and PSP groups at 3months (+0.3 vs +0.2, p=0.8), and 6months (+0.6 vs +0.2, p=0.2).

Conclusions

This nurse-delivered patient-support program did not significantly improve medication adherence or quality-of-life beyond standard care at short and medium-term time-points. Simply discussing and measuring adherence improved mesalamine adherence in both groups in this study.

Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Rose 1 / East, BIDMC, 330 Brookline Ave, Boston, MA 02215, United States

Corresponding Author InformationCorresponding author. Tel.: +1 617 667 3197; fax: +1 617 667 1171.

 Material from this manuscript was presented at Digestive Disease Week, Chicago IL, May 30–June 3rd 2009.

PII: S1873-9946(09)00107-X

doi:10.1016/j.crohns.2009.10.002


View previous. 9 of 21 View next.